Zymeworks Inc Registered Shs ZYME
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Zymeworks, Roche Enter Collaboration to Develop Experimental Lung Cancer Drug
-
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
-
Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma
-
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results
-
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
-
Zymeworks Completes Acquisition of Theravance Biopharma
-
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
-
Zymeworks Announces Participation in Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $28.44
- Day Range
- $27.28–28.77
- 52-Week Range
- $16.00–31.34
- Bid/Ask
- $25.60 / $29.29
- Shares Outstanding
- 71.75M
- Market Cap
- $2.02B
- Volume/Avg
- 1M / 853,940
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 56.77
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 1.81%
Company Profile
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 264
- Website
- https://www.zymeworks.com
Valuation
|
Metric
|
ZYME
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 25.27 |
Price/Sales | 56.77 |
Price/Cash Flow | — |
Price/Earnings
ZYME
Financial Strength
|
Metric
|
ZYME
|
|---|---|
Quick Ratio | 5.86 |
Current Ratio | 6.32 |
Interest Coverage | — |
Quick Ratio
ZYME
Profitability
|
Metric
|
ZYME
|
|---|---|
Return on Assets (Normalized) | −28.87% |
Return on Equity (Normalized) | −50.15% |
Return on Invested Capital (Normalized) | −48.11% |
Return on Assets
ZYME
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#>Tg?&% | LOCK|D>BYj | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|sVM&sb | LOCK|<?&%? | $83B | |||
| Moderna Inc
MRNA
| LOCK|P%jJwt? | LOCK|&<l | $80B | |||
| argenx SE ADR
ARGX
| LOCK|!W!&$M | LOCK|$j | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|qY?pDw | LOCK|#< | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%#M>qw | LOCK|Dx&&J | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>y!j@<Qy | LOCK|F>b?& | $28B | |||
| Incyte Corp
INCY
| LOCK|$L??M<f | LOCK|bQ> | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|?>sxp# | LOCK|!@m | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Z$?w<VT | LOCK|#M | $14B |
United States